Ilic D et al., 2013-01-31: Cochrane review of five RCTs of prostate cancer screening (mainly PSA). Pooled data showed no significant reduction in prostate cancer-specific or overall mortality; benefits were confined to a pre-specified subgroup in ERSPC, while harms from overdiagnosis and overtreatment were frequent.
Prostate cancer screening did not significantly decrease prostate cancer-specific mortality in a combined meta-analysis of five RCTs.
Abstract (AUTHORS' CONCLUSIONS)
Ilic D et al., 2013-01-31: Cochrane review of five RCTs of prostate cancer screening (mainly PSA). Pooled data showed no significant reduction in prostate cancer-specific or overall mortality; benefits were confined to a pre-specified subgroup in ERSPC, while harms from overdiagnosis and overtreatment were frequent. Funder: internal – University of Florida Department of Urology and Malcom Randall VA Medical Center; external – Dennis W. Jahnigen Career Development Scholars Award, American Geriatrics Society. Conflicts: 'None'. Test: PSA (and DRE, for which no independent study was found); assay makers not named. Comparator: no screening / usual care. PMC8406915. Study type: review.
